PMID- 38149018
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240325
IS  - 2590-0064 (Electronic)
IS  - 2590-0064 (Linking)
VI  - 23
DP  - 2023 Dec
TI  - Emulsifying Lipiodol with pH-sensitive DOX@HmA nanoparticles for hepatocellular 
      carcinoma TACE treatment eliminate metastasis.
PG  - 100873
LID - 10.1016/j.mtbio.2023.100873 [doi]
LID - 100873
AB  - Lipiodol-based transcatheter arterial chemoembolization (TACE) is currently the 
      predominant and first-line treatment option recommended by the global standard 
      for unresectable hepatocellular carcinoma (HCC). However, the unstable emulsion 
      of Lipiodol causes a substantial proportion of chemotherapy drugs to enter the 
      circulation system, leading to poor accumulation in cancer tissues and unexpected 
      side effects of chemotherapy drugs. Herein, we emulsified Lipiodol with a 
      pH-sensitive drug delivery system assembled from hexahistidine and zinc ions 
      (HmA) with a super-high loading capacity of doxorubicin (DOX) and a promising 
      ability to penetrate bio-barriers for the effective treatment of HCC by TACE. In 
      vitro tests showed that DOX@HmA was comparable to free DOX in killing HCC cells. 
      Impressively, during the in vivo TACE treatment, the anti-tumor efficacy of 
      DOX@HmA was significantly greater than that of free DOX, indicating that DOX@HmA 
      increased the accumulation of DOX in tumor. Emulsifying Lipiodol with 
      pH-sensitive DOX@HmA significantly inhibited cell regeneration and tumor 
      angiogenesis and decreased the systemic side effects of chemotherapy, especially 
      by suppressing pulmonary metastasis in liver VX2 tumors in rabbits by inhibiting 
      epithelial-mesenchymal transition (EMT). Emulsifying tumor 
      microenvironment-responsive drug delivery systems (DDSs) with Lipiodol could be a 
      new strategy for clinical TACE chemotherapy with potentially enhanced HCC 
      treatment.
CI  - (c) 2023 The Author(s).
FAU - Shi, Qing
AU  - Shi Q
AD  - Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of 
      Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, 
      Wenzhou, 325000, Zhejiang, China.
FAU - Zhang, Xingxing
AU  - Zhang X
AD  - Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of 
      Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, 
      Wenzhou, 325000, Zhejiang, China.
AD  - Shanghai University of Medicine ＆ Health Sciences Affiliated Sixth People＇s 
      Hospital South Compus, Shanghai, 201499, China.
FAU - Wu, Minmin
AU  - Wu M
AD  - Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of 
      Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, 
      Wenzhou, 325000, Zhejiang, China.
FAU - Xia, Yuhan
AU  - Xia Y
AD  - Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of 
      Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, 
      Wenzhou, 325000, Zhejiang, China.
FAU - Pan, Yating
AU  - Pan Y
AD  - Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of 
      Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, 
      Wenzhou, 325000, Zhejiang, China.
FAU - Weng, Jialu
AU  - Weng J
AD  - Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of 
      Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, 
      Wenzhou, 325000, Zhejiang, China.
FAU - Li, Na
AU  - Li N
AD  - Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of 
      Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, 
      Wenzhou, 325000, Zhejiang, China.
AD  - Wenzhou Institute, Wenzhou Key Laboratory of Perioperative Medicine, University 
      of Chinese Academy of Sciences, Wenzhou, 325001, China.
FAU - Zan, Xingjie
AU  - Zan X
AD  - Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of 
      Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, 
      Wenzhou, 325000, Zhejiang, China.
AD  - Wenzhou Institute, Wenzhou Key Laboratory of Perioperative Medicine, University 
      of Chinese Academy of Sciences, Wenzhou, 325001, China.
FAU - Xia, Jinglin
AU  - Xia J
AD  - Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of 
      Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, 
      Wenzhou, 325000, Zhejiang, China.
AD  - Liver Cancer Institute, Zhongshan Hospital of Fudan University, Shanghai, 200032, 
      China.
AD  - National Clinical Research Center for Interventional Medicine, Shanghai, 200032, 
      China.
LA  - eng
PT  - Journal Article
DEP - 20231129
PL  - England
TA  - Mater Today Bio
JT  - Materials today. Bio
JID - 101757228
EIN - Mater Today Bio. 2023 Dec 26;25:100916. PMID: 38524904
PMC - PMC10750100
OTO - NOTNLM
OT  - Doxorubicin
OT  - Hexahistidine-metal
OT  - Liver cancer
OT  - Transcatheter arterial chemoembolization
OT  - pH-sensitive nanoparticles
COIS- The authors declare that they have no known competing financial interests or 
      personal relationships that could have appeared to influence the work reported in 
      this paper.
EDAT- 2023/12/27 06:42
MHDA- 2023/12/27 06:43
PMCR- 2023/11/29
CRDT- 2023/12/27 03:44
PHST- 2023/09/27 00:00 [received]
PHST- 2023/11/05 00:00 [revised]
PHST- 2023/11/17 00:00 [accepted]
PHST- 2023/12/27 06:43 [medline]
PHST- 2023/12/27 06:42 [pubmed]
PHST- 2023/12/27 03:44 [entrez]
PHST- 2023/11/29 00:00 [pmc-release]
AID - S2590-0064(23)00333-2 [pii]
AID - 100873 [pii]
AID - 10.1016/j.mtbio.2023.100873 [doi]
PST - epublish
SO  - Mater Today Bio. 2023 Nov 29;23:100873. doi: 10.1016/j.mtbio.2023.100873. 
      eCollection 2023 Dec.